• Je něco špatně v tomto záznamu ?

Gemtuzumab ozogamicin plus midostaurin in conjunction with standard intensive therapy for FLT3- mutated acute myeloid leukemia patients - Czech center experience

B. Weinbergerová, M. Čerňan, T. Kabut, L. Semerád, N. Podstavková, T. Szotkowski, I. Ježíšková, J. Mayer

. 2023 ; 108 (10) : 2826-2829. [pub] 20231001

Jazyk angličtina Země Itálie

Typ dokumentu dopisy

Perzistentní odkaz   https://www.medvik.cz/link/bmc24001194

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24001194
003      
CZ-PrNML
005      
20240213094428.0
007      
ta
008      
240109s2023 it f 000 0|eng||
009      
AR
024    7_
$a 10.3324/haematol.2022.282263 $2 doi
035    __
$a (PubMed)36815379
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a it
100    1_
$a Weinbergerová, Barbora $u Department of Internal Medicine - Hematology and Oncology, Masaryk University, Brno, Czech Republic; Department of Internal Medicine - Hematology and Oncology, University Hospital Brno, Brno, Czech Republic. Weinbergerova.Barbora@fnbrno.cz
245    10
$a Gemtuzumab ozogamicin plus midostaurin in conjunction with standard intensive therapy for FLT3- mutated acute myeloid leukemia patients - Czech center experience / $c B. Weinbergerová, M. Čerňan, T. Kabut, L. Semerád, N. Podstavková, T. Szotkowski, I. Ježíšková, J. Mayer
650    _2
$a lidé $7 D006801
650    _2
$a gemtuzumab $7 D000079982
650    12
$a akutní myeloidní leukemie $x farmakoterapie $x genetika $7 D015470
650    _2
$a staurosporin $x terapeutické užití $7 D019311
650    _2
$a tyrosinkinasa 3 podobná fms $x genetika $7 D051941
651    _2
$a Česká republika $7 D018153
655    _2
$a dopisy $7 D016422
700    1_
$a Čerňan, Martin $u Department of Hemato-Oncology, Faculty of Medicine and Dentistry, Palacký University Olomouc and University Hospital Olomouc, Olomouc, Czech Republic
700    1_
$a Kabut, Tomáš $u Department of Internal Medicine - Hematology and Oncology, Masaryk University, Brno, Czech Republic; Department of Internal Medicine - Hematology and Oncology, University Hospital Brno, Brno, Czech Republic
700    1_
$a Semerád, Lukáš $u Department of Internal Medicine - Hematology and Oncology, Masaryk University, Brno, Czech Republic; Department of Internal Medicine - Hematology and Oncology, University Hospital Brno, Brno, Czech Republic
700    1_
$a Podstavková, Natália $u Department of Internal Medicine - Hematology and Oncology, Masaryk University, Brno, Czech Republic; Department of Internal Medicine - Hematology and Oncology, University Hospital Brno, Brno, Czech Republic
700    1_
$a Szotkowski, Tomáš $u Department of Hemato-Oncology, Faculty of Medicine and Dentistry, Palacký University Olomouc and University Hospital Olomouc, Olomouc, Czech Republic
700    1_
$a Ježíšková, Ivana $u Department of Internal Medicine - Hematology and Oncology, Masaryk University, Brno, Czech Republic; Department of Internal Medicine - Hematology and Oncology, University Hospital Brno, Brno, Czech Republic
700    1_
$a Mayer, Jiří $u Department of Internal Medicine - Hematology and Oncology, Masaryk University, Brno, Czech Republic; Department of Internal Medicine - Hematology and Oncology, University Hospital Brno, Brno, Czech Republic
773    0_
$w MED00001963 $t Haematologica $x 1592-8721 $g Roč. 108, č. 10 (2023), s. 2826-2829
856    41
$u https://pubmed.ncbi.nlm.nih.gov/36815379 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20240109 $b ABA008
991    __
$a 20240213094425 $b ABA008
999    __
$a ok $b bmc $g 2049666 $s 1210888
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2023 $b 108 $c 10 $d 2826-2829 $e 20231001 $i 1592-8721 $m Haematologica $n Haematologica $x MED00001963
LZP    __
$a Pubmed-20240109

Najít záznam

Citační ukazatele

Možnosti archivace